Follow
Felix Vaura
Felix Vaura
Institute of Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki
Verified email at helsinki.fi - Homepage
Title
Cited by
Cited by
Year
FinnGen provides genetic insights from a well-phenotyped isolated population
MI Kurki, J Karjalainen, P Palta, TP Sipilä, K Kristiansson, KM Donner, ...
Nature 613 (7944), 508-518, 2023
8012023
Stroke genetics informs drug discovery and risk prediction across ancestries
A Mishra, R Malik, T Hachiya, T Jürgenson, S Namba, DC Posner, ...
Nature 611 (7934), 115-123, 2022
1832022
Polygenic risk scores predict hypertension onset and cardiovascular risk
F Vaura, A Kauko, K Suvila, AS Havulinna, N Mars, V Salomaa, FinnGen, ...
Hypertension 77 (4), 1119-1127, 2021
832021
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a Phase I/II Clinical Trial
R Virtakoivu, JH Rannikko, M Viitala, F Vaura, A Takeda, T Lönnberg, ...
Clinical Cancer Research 27 (15), 4205-4220, 2021
352021
Genetic, molecular, and cellular determinants of sex-specific cardiovascular traits
F Vaura, J Palmu, J Aittokallio, A Kauko, T Niiranen
Circulation Research 130 (4), 611-631, 2022
242022
Novel biomarkers for diagnosing periprosthetic joint infection from synovial fluid and serum
H Keemu, F Vaura, A Maksimow, M Maksimow, A Jokela, M Hollmén, ...
JBJS Open Access 6 (2), e20, 2021
192021
Sex differences in genetic risk for hypertension
A Kauko, J Aittokallio, F Vaura, H Ji, JE Ebinger, T Niiranen, S Cheng
Hypertension 78 (4), 1153-1155, 2021
162021
The genomics of heart failure: design and rationale of the HERMES consortium
RT Lumbers, S Shah, H Lin, T Czuba, A Henry, DI Swerdlow, A Mälarstig, ...
ESC heart failure 8 (6), 5531-5541, 2021
112021
Polygenic Risk Scores for Predicting Adverse Outcomes After Coronary Revascularization
J Aittokallio, A Kauko, F Vaura, V Salomaa, T Kiviniemi, RB Schnabel, ...
The American Journal of Cardiology 167, 9-14, 2022
72022
Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
P Bono, R Virtakoivu, F Vaura, P Jaakkola, S Shetty, A Thibault, ...
Journal of Clinical Oncology 38 (15_suppl), 3097-3097, 2020
72020
Associations of polygenic risk scores for preeclampsia and blood pressure with hypertensive disorders of pregnancy
J Nurkkala, A Kauko, H Laivuori, T Saarela, JS Tyrmi, F Vaura, S Cheng, ...
Journal of Hypertension 41 (3), 380, 2023
42023
Unsupervised hierarchical clustering identifies a metabolically challenged subgroup of hypertensive individuals
FC Vaura, VV Salomaa, IM Kantola, R Kaaja, L Lahti, TJ Niiranen
The Journal of Clinical Hypertension 22 (9), 1546-1553, 2020
42020
Multi-Trait Genetic Analysis Reveals Clinically Interpretable Hypertension Subtypes
F Vaura, H Kim, MS Udler, FinnGen*, V Salomaa, L Lahti, T Niiranen
Circulation: Genomic and Precision Medicine 15 (4), e003583, 2022
22022
Verenpainetaudin geneettinen tausta
F Vaura, T Niiranen
12022
The system can't perform the operation now. Try again later.
Articles 1–14